Shanghai Aladdin Biochemical Technology Co., Ltd. Feb 5, 2025 Self-assembling peptide with dual function of cell penetration and antibacterial as a nano weapon to combat intracellular bacteria - Science | AAAS
Illumina Feb 5, 2025 Illumina placed on China’s unreliable entity list - MedTech Dive #MedTech Dive #unreliable entity
FAMECO Feb 4, 2025 Surplus Solutions Expands Global Offerings with Refurbished Analytical and Medical Equipment, Supported by New Brand and Website Launch - NTB Kommunikasjon
Bio-Gene Technology Ltd Jan 31, 2025 ASX Runners of the Week: Bio-Gene, Alterity, Aston & Canterbury - SMH.com.au
Lonza News Jan 30, 2025 While Lonza's sales slipped in '24, CDMO touts stronger position heading into new year - Fierce Pharma #CDMO touts #Fierce Pharma
Illumina Jan 25, 2025 CSR News Feed | Explore the latest corporate social responsibility news from Illumina - Illumina #latest corporate #corporate social
Cytiva (Google News) Jan 24, 2025 Cellular Origins and Cytiva Are Collaborating To Deliver Automated Robotic Manufacturing Capabilities for Cell and Gene Therapies - Technology Networks #Deliver Automated #Automated Robotic
Lonza News Jan 23, 2025 CDMO Joinn Biologics snaps up China biologics plant from Lonza in push to tackle Asia-Pacific market - Fierce Pharma #CDMO Joinn #Joinn Biologics
Beijing Solarbio Science & Technology Co.,Ltd. Jan 22, 2025 Multiple Enzymes Expressed by the Gut Microbiota Can Transform Typhaneoside and Are Associated with Improving Hyperlipidemia - Wiley
Cytiva (Google News) Jan 21, 2025 Cytiva and Cellular Origins Team Up on Delivering Automated CGT Manufacturing - BioPharm International #Cellular Origins #Origins Team
Lonza News Jan 17, 2025 JPM 2025: Lonza shares outlook on CHI exit and acquisition strategy - Pharmaceutical Technology #Lonza shares #Pharmaceutical Technology
Cytiva (Google News) Jan 16, 2025 Cellular Origins, Cytiva Partner on Robotic Mfg. Capabilities for CGTs - Contract Pharma #Cytiva Partner #Robotic Mfg
Shanghai Fuheng Biotechnology Co., Ltd. Jan 15, 2025 Injectable supramolecular hydrogel co-loading abemaciclib/NLG919 for neoadjuvant immunotherapy of triple-negative breast cancer - Nature